INTRODUCTION The equity-focused ILANA study evaluated feasibility, acceptability, appropriateness of delivering on-label two-monthly cabotegravir and rilpivirine (CAB+RPV) injections for HIV-1 therapy in clinics and community settings. METHODS The study, which mandated inclusive recruitment, was conducted May-December 2022 at six UK sites. Injections were delivered in clinic (months 1-6), and in clinic or community setting according to patient choice (months 6-12). Surveys were completed at baseline, M4 and M12 using validated measures for feasibility (FIM), acceptability (AIM), and appropriateness (IAM). Primary endpoint: proportion of participants agreeing that the injection and community setting were feasible (FIM>4) at M12. Fourteen participants completed interviews at baseline and M12. RESULTS Community settings offered by sites included: home visits (n=3), HIV support organisations (n=2), community clinic (n=1). Of 114 participants,54% were female, 70% racially minoritised and 40% aged >50. 27/114 chose to receive injections in community settings. FIM/AIM/IAM scores at M12 were high for the injection (79.0-87.4%) and lower for the community setting (44.2-47.4%) overall. Subgroup analyses indicated differences in scores by gender and ethnicity. Among those who attended the community, FIM/AIM/IAM scores for the community setting at M12 were high (73.1-80.8%). Concerns about stigma, inconvenience, and losing access to trusted clinicians negatively influenced perceptions of receiving injections at community settings, amongst other factors. CONCLUSION CAB+RPV injections were considered highly feasible, acceptable, and appropriate, however few chose community delivery. Those that chose community delivery found it highly acceptable and feasible. Further exploration of CAB+RPV delivery in alternative community sites not offered (e.g. primary care or pharmacies) is warranted.

中文翻译：

---

HIV 感染者对在英国诊所和社区环境中实施长效卡博特韦加利匹韦林的看法：反性别歧视、反种族主义、反年龄主义 ILANA 研究的结果。


引言 以公平为重点的 ILANA 研究评估了在诊所和社区环境中提供标签上每两个月一次的卡博特韦和利匹韦林 （CAB+RPV） 注射用于 HIV-1 治疗的可行性、可接受性和适当性。方法 该研究强制要求包容性招聘，于 2022 年 5 月至 12 月在英国的六个地点进行。注射在诊所 （1-6 个月） 进行，并根据患者的选择在诊所或社区 （6-12 个月） 进行。使用经过验证的可行性 （FIM） 、可接受性 （AIM） 和适当性 （IAM） 措施在基线、M4 和 M12 完成调查。主要终点：同意注射和社区设置在 M12 时可行的参与者比例 （FIM>4）。14 名参与者在基线和 M12 时完成了访谈。结果 站点提供的社区环境包括：家访 （n=3）、HIV 支持组织 （n=2）、社区诊所 （n=1）。在 114 名参与者中，54% 是女性，70% 是少数种族，40% 是 >50 岁。27/114 选择在社区环境中接受注射。总体而言，注射组 M12 的 FIM/AIM/IAM 评分较高 （79.0-87.4%），社区环境较低 （44.2-47.4%）。亚组分析表明性别和种族的分数存在差异。在参加社区的人中，社区环境的 FIM/AIM/IAM 分数在 M12 很高 （73.1-80.8%）。除其他因素外，对耻辱感、不便和无法获得值得信赖的临床医生的担忧对在社区环境中接受注射的看法产生了负面影响。结论 CAB+RPV 注射被认为高度可行、可接受和适当，但很少有人选择社区给药。那些选择社区交付的人认为它非常可接受和可行。 有必要在未提供的其他社区场所（例如初级保健或药房）进一步探索 CAB+RPV 的递送。